{"url_path":"/sec/aytu/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 LEGAL PROCEDINGS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1385818/0001437749-26-016721-index.html","accession_number":"0001437749-26-016721","cik":"0001385818","ticker":"AYTU","issuer_name":"AYTU BIOPHARMA, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1385818/0001437749-26-016721-index.html","primary_entity_key":"0001385818","primary_entity_name":"AYTU BIOPHARMA, INC"},"word_count":169,"has_tables":true,"body_markdown":"**ITEM 1. LEGAL PROCEDINGS**\n\n \n\nFrom time to time, we become involved in or are threatened with legal disputes arising from our business and operations in the normal course of business. Most of these disputes are not likely to have a material effect on our business, financial condition, or operations. There were no new material legal proceedings that were initiated or terminated during the period covered by this report and there have been no material developments in the material proceedings identified in Part I, Item 3 in our [2025 Form 10-K](http://www.sec.gov/ix?doc=/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm). For a description of our material pending legal proceedings, see *Note 13 - **Commitments and Contingencies* of the notes to the unaudited consolidated financial statements included in Part I, Item 1 of this Form 10-Q, which is incorporated herein by reference. As of the filing of this report, no legal proceedings are pending against us that we believe individually or collectively are likely to have a materially adverse effect upon our financial condition, results of operations, or cash flows."}